SIC
SUPN icon

Samalin Investment Counsel’s Supernus Pharmaceuticals SUPN Stock Holding History

Samalin Investment Counsel’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-200
Closed -$4K – 467
2019
Q4 		$4K Buy
+200
New +$4.86K ﹤0.01% 482

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Samalin Investment Counsel's SUPN Position: Q1 2020 in Review

Samalin Investment Counsel sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 200 shares — an estimated $4K sold.

Samalin Investment Counsel first reported a position in SUPN in Q4 2019 and held it in 1 quarter. The position peaked at $4K in Q4 2019. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

  • Samalin Investment Counsel reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Samalin Investment Counsel sold 200 Supernus Pharmaceuticals shares in Q1 2020, an estimated $4K.
  • Samalin Investment Counsel first reported a position in Supernus Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Samalin Investment Counsel's Supernus Pharmaceuticals position peaked at $4K in Q4 2019.
  • 208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on Samalin Investment Counsel's 13F filing for Q1 2020, filed 4 May 2020.